The factory, which will be located on a 42 hectare greenfield site is planned to be operational by 2023, will be run by Recipharm and will mirror the company’s new fill finish line at its facility in Monts, France on a larger scale.
Via the Russian Direct Investment Fund, the authorities established a mechanism for using foreign sites, where the substance for the production of vaccines is sent to, the minister said.
The plant is actively expanding its portfolio and introducing new production facilities. Bilateral cooperation between government and business will continue in the future.
It is envisaged to implement the project in three stages from 2021 to 2024, the amount of investment from the company "SOLYPHAR" will be more than 20 million US dollars, in accordance to the international GMP standards.
Pharmaceutical holding Nacimbio of Rostec State Corporation will create new production facilities at NPO Microgen subsidiaries in Ufa, Perm and Tomsk. Biotechnology products, including...